The mitotic checkpoint gene Mad2 has been shown in metazoans to be an important part of the mitotic checkpoint apparatus through biochemical experiments. Mad2 is a component of the machinery which arrests a cell prior to the metaphase to anaphase transition if all the chromosomes are not attached to the mitotic spindle apparatus. The main goal of the research being proposed is to determine if complete or partial loss of Mad2 function in mammalian cells leads to a loss of mitotic checkpoint control, genomic instability and/or tumor progression either under normal growth conditions or when the checkpoint apparatus is challenged with mitotic spindle inhibitors. It has not yet been demonstrated whether the loss of any component of the mitotic checkpoint mechanism in vertebrates leads to chromosome instability or cellular transformation. Mice and human cells that have one copy of the Mad2 gene inactivated by gene targeting will be further analyzed with respect to defects in the mitotic checkpoint pathway. It will be determined whether such cells can arrest appropriately during mitosis when the mitotic spindle is inhibited, and if not, the consequences of this failure on whole chromosome loss rates and tumorigenic properties. In addition, the dosage of Mad2 will be decreased in both mouse and human cells by the introduction of dominant negative Mad2 alleles, or conditional inactivation of the second Mad2 allele. These cells, likely to have a more severe mitotic checkpoint defect, will also be analyzed for changes in chromosome stability and alterations in tumorigenic properties. In this way, the role of the mitotic checkpoint pathway in cancer initiation and/or progression in mammals will be assessed.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM054601-04A1
Application #
6261280
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Zatz, Marion M
Project Start
1997-05-01
Project End
2005-04-30
Budget Start
2001-05-01
Budget End
2002-04-30
Support Year
4
Fiscal Year
2001
Total Cost
$278,346
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Horwitz, Briana N; Marceau, Kristine; Narusyte, Jurgita et al. (2015) Parental criticism is an environmental influence on adolescent somatic symptoms. J Fam Psychol 29:283-9
Michel, Loren; Diaz-Rodriguez, Elena; Narayan, Gopeshwar et al. (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 101:4459-64
Wassmann, Katja; Liberal, Vasco; Benezra, Robert (2003) Mad2 phosphorylation regulates its association with Mad1 and the APC/C. EMBO J 22:797-806
Hernando, E; Orlow, I; Liberal, V et al. (2001) Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer 95:223-7
Wassmann, K; Benezra, R (2001) Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 11:83-90
Dobles, M; Liberal, V; Scott, M L et al. (2000) Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 101:635-45
Wassmann, K; Benezra, R (1998) Mad2 transiently associates with an APC/p55Cdc complex during mitosis. Proc Natl Acad Sci U S A 95:11193-8